Search
Jaccus-B Shares Surge Over 17% Post-Earnings, with Mid-Year Revenue Climbing to Nearly RMB 45.7 Million
2025-09-01 /
Read about 0 minute
Author：小编
Jaccus-B has announced its mid-year financial results, reporting revenues of RMB 45.664 million. Notably, the loss attributable to the company's shareholders has significantly narrowed by 65.1% year-on-year. The company's share price witnessed a remarkable surge of 16.89%, closing at HK$9.48, primarily driven by a milestone payment received under its license agreement with Allis. Furthermore, Jaccus-B aims to submit an Investigational New Drug (IND) application for its HER2-STING immune-activating antibody-drug conjugate (iADC) clinical candidate, JAB-BX467, in 2026, underscoring its positive advancements in the realm of research and development.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
